Tvardi Therapeutics (TVRD) Other Accumulated Expenses (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Other Accumulated Expenses of $179000.0 for Q1 2026, down 44.24% sequentially from $321000.0 in Q4 2025.
Tvardi Therapeutics (TVRD) Other Accumulated Expenses (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Other Accumulated Expenses for 8 years, with the latest figure at $179000.0 in Q1 2026.
- Quarterly Other Accumulated Expenses changed N/A year-over-year to $179000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $179000.0 (changed N/A YoY) and the FY2025 annual result came in at $321000.0, up 3912.5% from the prior year.
- Other Accumulated Expenses slipped to $179000.0 in Q1 2026 per TVRD's latest filing, from $321000.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $452000.0 in Q3 2025 and troughed at $8000.0 in Q4 2024.
- A 3-year average of $281600.0 and a median of $321000.0 in 2025 frame the typical range for Other Accumulated Expenses.
- The widest YoY moves for Other Accumulated Expenses: up 3912.5% in 2025, down 3912.5% in 2025.
- Over 3 years, Other Accumulated Expenses stood at $8000.0 in 2024, then surged by 3912.5% to $321000.0 in 2025, then tumbled by 44.24% to $179000.0 in 2026.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $179000.0, $321000.0, and $452000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 179,000.00 |
| Dec 31, 2025 | 321,000.00 |
| Sep 30, 2025 | 452,000.00 |
| Jun 30, 2025 | 448,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2018 | 123,000.00 |
| Jun 30, 2018 | 86,000.00 |
| Dec 31, 2017 | 73,000.00 |
| Dec 31, 2015 | 186,000.00 |
| Sep 30, 2015 | 86,000.00 |
| Jun 30, 2015 | 41,000.00 |
| Mar 31, 2015 | 57,000.00 |
| Dec 31, 2014 | 112,000.00 |
| Sep 30, 2014 | 36,000.00 |
| Jun 30, 2014 | 136,000.00 |
| Mar 31, 2014 | 22,000.00 |
| Dec 31, 2013 | 55,000.00 |